TCL Archive Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says. May 7, 2004
TCL Archive GAO Study Claiming No Benefit Seen In Adjuvant Breast Cancer Treatment Flawed, NCI Responds April 21, 1989